Incyte Corporation $INCY Stock Sold by Ashton Thomas Private Wealth LLC

Key Points

• Ashton Thomas Private Wealth cut its Incyte stake by 35.7% in the third quarter, selling 12,750 shares and ending the period with 23,006 shares valued at about $2.79 million.
• Incyte’s latest quarter brought $1.56 billion in revenue, up 14% year over year, and an EPS loss of $3.60 that was narrower than analysts expected.
• Analyst sentiment is mixed: the stock has an average “Hold” rating and a $132.86 average price target. Upcoming hematology data at ASH 2026 is one potential catalyst noted by bullish analysts.

Ashton Thomas Private Wealth LLC decreased its position in shares of Incyte Corporation (NASDAQ:INCY - Free Report) by 35.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,006 shares of the biopharmaceutical company's stock after selling 12,750 shares during the period. Ashton Thomas Private Wealth LLC's holdings in Incyte were worth $2,792,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of INCY. BlackRock Inc. acquired a new position in Incyte in the 2nd quarter valued at $2,044,189,000. Legal & General Group Plc bought a new position in Incyte in the second quarter worth $182,054,000. Caisse de depot et placement du Quebec acquired a new stake in shares of Incyte during the 2nd quarter valued at about $155,360,000. Deutsche Bank AG bought a new stake in shares of Incyte in the 2nd quarter valued at approximately $143,172,000. Finally, Bank of New York Mellon Corp bought a new stake in Incyte in the second quarter valued at $110,279,000. Institutional investors and hedge funds own 96.97% of the company's stock.

More Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Leerink Partners reaffirmed its Buy rating and set a $150 price target, indicating confidence in Incyte’s prospects. Article
• Positive Sentiment: Incyte plans to present new hematology data at ASH 2026. Canaccord Genuity maintained its Buy rating and $152 target, citing upcoming data for ’989 as support for its view; the results could provide updates on pipeline potential. Article Analyst report
• Neutral Sentiment: Incyte raised Bernstein’s price target to $108 from $104. The increase is modest, and the new target remains below the recent share price. Article
• Neutral Sentiment: The company awarded grants supporting projects focused on graft-versus-host disease (GVHD). The program underscores its engagement in the area but is unlikely to materially affect near-term revenue. Article
• Neutral Sentiment: Insider Thomas Tray sold 610 shares under a pre-arranged Rule 10b5-1 plan, retaining more than 21,000 shares afterward. The planned, relatively small sale offers limited directional signal. Article

Analysts Set New Price Targets

Several analysts have recently weighed in on INCY shares. Piper Sandler raised their price objective on shares of Incyte from $110.00 to $130.00 and gave the stock an "overweight" rating in a report on Monday, August 17th. Guggenheim upped their target price on shares of Incyte from $136.00 to $150.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. TD Cowen raised their price target on Incyte from $138.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, October 21st. Leerink Partners lowered their target price on shares of Incyte from $154.00 to $150.00 and set an "outperform" rating for the company in a research note on Thursday. Finally, Stifel Nicolaus increased their price target on Incyte from $145.00 to $157.00 and gave the stock a "buy" rating in a report on Monday, October 5th. Eleven research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Incyte presently has an average rating of "Hold" and an average price target of $132.86.

Insider Activity at Incyte

In other Incyte news, insider Thomas Tray sold 610 shares of the stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $118.96, for a total transaction of $72,565.60. Following the transaction, the insider owned 21,126 shares in the company, valued at $2,513,148.96. This represents a 2.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo J. Cagnoni sold 2,642 shares of the firm's stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $112.71, for a total value of $297,779.82. Following the transaction, the insider owned 183,200 shares in the company, valued at approximately $20,648,472. This trade represents a 1.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 14,053 shares of company stock valued at $1,726,519. 16.20% of the stock is currently owned by insiders.

Incyte Stock Performance

Incyte stock opened at $119.65 on Monday. Incyte Corporation has a 52 week low of $89.25 and a 52 week high of $132.60. The stock has a 50-day simple moving average of $119.62 and a 200 day simple moving average of $108.51. The stock has a market capitalization of $24.39 billion, a P/E ratio of 63.64, a PEG ratio of 4.36 and a beta of 0.78.

Incyte (NASDAQ:INCY - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, beating analysts' consensus estimates of ($3.93) by $0.33. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The business had revenue of $1.56 billion for the quarter, compared to analysts' expectations of $1.46 billion. During the same quarter in the prior year, the business earned $2.26 EPS. The firm's revenue for the quarter was up 14.0% on a year-over-year basis. Research analysts forecast that Incyte Corporation will post 2.24 earnings per share for the current year.

About Incyte

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally.

Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.